Cost-effectiveness analysis of a quality-controlled mammography screening program from the swiss statutory health-care perspective: Quantitative assessment of the most influential factors

Value in Health

Volumn 10, Issue 1, 2007, Pages 42-53

  Neeser, Kurt ^a,e   Szucs, Thomas ^b   Bulliard, Jean Luc ^c   Bachmann, Gaudenz ^d   Schramm, Wendelin ^a  

^a Swiss Institute for Medical Decision Support (SIMEDES)   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d Health Department of Canton St Gallen   (Switzerland)

^e Department of Modelling and Evaluation ^*  (Switzerland)

Author keywords

Cost effectiveness; Health economics; Quality controlled mammography Screening; Switzenland

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGISTRY; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; FEMALE; HEALTH CARE SYSTEM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; SCREENING; SWITZERLAND;

EID: 33846512958     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2006.00143.x     Document Type: Article

References (57)

1. Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. Public Health Paper No. 34. Geneva: World Health Organisation (WHO), 1968.
2. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon: IARC CancerBase, IARCPress, 5, 2004.
3. Parkin DM. Breast cancer in Europe: epidemiology and forecast. Electron J Oncol 1999;2:45-64.
4. Bonadona V, Lasset C. [Inherited predisposition to breast cancer. after the BRCA1 and BRCA2 genes, what next?]. Bull Cancer 2003;90:587-94.
5. Tjonneland A, Thomsen BL, Stripp C, et al. Alcohol intake, drinking patterns and risk of postmenopausal breast cancer in Denmark: a prospective cohort study. Cancer Causes Control 2003;14:277-84.
6. Morimoto LM, White E, Chen Z, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51.
7. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27.
8. Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish women's lifestyle and health cohort study. Cancer Epidemiol Biomarkers Prev 2002;11:1375-81.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-27.
10. Humphrey LL, Helfand M, Chan BK, Woolf SH. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:347-60.
11. Nystrom L, Andersson I, Bjurstam N, et al. Long-term effects of mammography screening: updated overview of the Swedish randomised trials. Lancet 2002;359:909-19.
12. Aubard Y, Genet D, Eyraud JL, et al. Impact of screening on breast cancer detection. Retrospective comparative study of two periods ten years apart. Eur J Gynaecol Oncol 2002;23:37-41.
13. International Agency for Research on Cancer, WHO. 5. Effectiveness of Screening. In: Vainio H, Bianchini F, ed., Breast Cancer Screening - IARC handbooks of cancer prevention volume 7. Lyon: IARC press, 2002:119-56.
14. International Agency for Research on Cancer, WHO. 7. Summary. In: Vainio H, Bianchini F, ed., Breast Cancer Screening - IARC handbooks of cancer prevention volume 7. Lyon: IARC press, 2002:171-6.
15. Frisell J, Lidbrink E. The Stockholm Mammographic Screening Trial: risks and benefits in age group 40-49 years. J Natl Cancer Inst Monogr 1997;22:49-51.
16. Kerlikowske K, Grady D, Rubin SM, et al. Efficacy of screening mammography. A meta-analysis. JAMA 1995;273:149-54.
17. Larsson LG, Andersson I, Bjurstam N, et al. Updated overview of the Swedish Randomized Trials on Breast Cancer Screening with Mammography: age group 40-49 at randomization. J Natl Cancer Inst Monogr 1997;22:57-61.
18. Carney PA, Miglioretti DL, Yankaskas BC, et al. Individual and combined effects of age, breast density, and hormone replacement therapy use on the accuracy of screening mammography. Ann Intern Med 2003;138:168-75.
19. Zappa M, Visioli CB, Ciatto S. Mammography screening in elderly women: efficacy and cost-effectiveness. Crit Rev Oncol Hematol 2003;46:235-9.
20. Shapiro S, Coleman EA, Broeders M, et al. Breast cancer screening programmes in 22 countries: current policies, administration and guidelines. International Breast Cancer Screening Network (IBSN) and the European Network of Pilot Projects for Breast Cancer Screening. Int J Epidemiol 1998;27:735-42.
21. Bulliard JL, De Landtsheer JP, Levi F. Results from the Swiss mammography screening pilot programme. Eur J Cancer 2003;39:1761-9.
22. Association of Swiss Cancer Registries. (the cantons of Basle, Geneva, Graubünden & Glarus, Neuchâtel, St-Gall & Appenzell, Tessin, Valais, Vaud and Zurich). Cancer in Switzerland. Statistics of Incidence (Vol. 1) and. Statistics of Mortality (Vol. 2). Available at http://www.asrt [Accessed December 2004].
23. Verkooijen HM, Fioretta G, Vlastos G, et al. Important increase of invasive lobular breast cancer incidence in Geneva, Switzerland. Int J Cancer 2003;104:778-81.
24. Levi F, Te VC, Randimbison L, La Vecchia C. Increase in lobular breast cancer incidence in Switzerland. Int J Cancer 2003;107:164-5.
25. Bulliard JL, La Vecchia C, Levi F. Diverging trends in breast cancer mortality within Switzerland. Ann Oncol 2006;17:57-9.
26. De Landtsheer JP, Delaloye JF, Hessler C, et al. [Organized screening for breast cancer: the Vaud experience]. Rev Med Suisse Romande 2000;120:501-10.
27. De Landtsheer JP, Delanoy Ortega B, Jemelin CL. Breast cancer screening: comparative analysis of three Swiss programs. Med Hyg 2000;58:1407-10.
28. Bulliard JL, De Landtsheer JP, Levi F. Reattendance in the Swiss mammography screening pilot programme. J Med Screen 2004;11:59-64.
29. Gotzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
30. Olsen O, Gotzsche PC. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2001;4:CD001877.
31. Duffy SW, Tabar L, Smith RA. The mammographic screening trials: commentary on the recent work by Olsen and Gotzsche. CA Cancer J Clin 2002;52:68-71.
32. Health Council of the Netherlands. The benefit of population screening for breast cancer with mammography. The Hag, Health Council of the Netherlands, 2002; publication no. 2002-03E.
33. U.S. Preventiver Services Task Force. Screening for breast cancer: recommendations and rationale. Ann Intern Med 2002;137:344-6.
34. Zwahlen M, Bopp M, Probst-Hensch NM. Mammography screening in Switzerland: limited evidence from limited data. Swiss Med Wkly 2004;134:295-306.
35. Perry N, Broeders M, de Wolf C, Tornberg S. Europe against Cancer. European Guidelines for Quality Assurance in Mammography Screening (3rd ed.). Luxembourg: European Communities, 2001.
36. Sterbefälle und Sterbeziffern wichtiger Todesursachen, nach Alter, Frauen (1998). In: Bundesamt für Statistik, eds., Statistisches Jahrbuch der Schweiz. Zürich: Verlag NZZ, 2002.
37. WHO Statistical Information System (WHOSIS). Table 1: Numbers and rates of registered deaths. Switzerland - 1999. Geneva: World Health Organization (WHO), 2004.
38. Coleman MP. Opinion: why the variation in breast cancer survival in Europe? Breast Cancer Res 1999;1:22-6.
39. Brown DW, French MT, Schweitzer ME, et al. Economic evaluation of breast cancer screening: a review. Cancer Pract 1999;7:28-33.
40. Levi F, Randimbison L, Te VC, La Vecchia C. Long-term mortality of women with a diagnosis of breast cancer. Oncology 2002;63:266-9.
41. Gisler R. Gesamtschweizerisches Programm für Mammographie-Screening. Abschlussbericht, Stiftung zur Früherkennung von Krebs. Bern: der 26 Mai, 2000.
42. Badreddine M. Coût moyen du dépistage du cancer du sein à Genève: comparaison entre deux modes de "screening." Université de Lausanne: Institut d'économie et management de la santé (iems). Lausanne, 2004.
43. Smala A, Beeler I, Szucs TD. Die Kosten körperlicher Inaktivität. Abteilung für Medizinische Ökonomie des Instituts für Sozial- und Präventivmedizin und des Universitätsspitals Zürich Rämistrasse 100 CH - 8091 Zürich und MERG - Forschungsgruppe Medizinische Ökonomie Paul - Gerhardt - Allee 42 D - 81245 München. 2001.
44. Martin BW, Beeler I, Szucs TD, et al. Volkswirtschaftlicher Nutzen der Gesundheitseffekte der körperlichen Aktivität: Erste Schätzungen für die Schweiz. Schweiz Z Sportmed Sporttraumatol 2001;49:84-6.
45. Bundesamt für Statistik. Kosten des Gesundheitswesens. Detaillierte Ergebnisse. und Entwicklung seit 1995, 2002.
46. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). Pharmacoeconomic Guidelines around the World. 1998. Available from: http://www.ispor.org/PEguidelines/countrydet.asp?c=25&t=1 [Accessed December 20, 2004].
47. Gold MR, Siegel JE, Russel LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
48. Rembold CM. Number needed to screen: development of a statistic for disease screening. BMJ 1998;317:307-12.
49. Barratt A, Howard K, Irwig L, et al. Model of outcomes of screening mammography: information to support informed choices. BMJ 2005;330:936.
50. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137:529-41.
51. Tengs TO, Adams ME, Pliskin JS, et al. Five-hundred life-saving interventions and their cost-effectiveness. Risk Anal 1995;15:369-90.
52. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992;146:473-81.
53. Kerlikowske K, Salzmann P, Phillips KA, et al. Continuing screening mammography in women aged 70 to 79 years: impact on life expectancy and cost-effectiveness. JAMA 1999;282:2156-63.
54. Mandelblatt J, Saha S, Teutsch S, et al. The cost-effectiveness of screening mammography beyond age 65 years: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2003;139:835-42.
55. Karesen R, Bo JK, Haustveit S, et al. [Cost-effectiveness of mammography screening in Norway]. Tidsskr Nor Laegeforen 1999;119:3553-9.
56. Wang H, Karesen R, Hervik A, Thoresen SO. Mammography screening in Norway: results from the first screening round in four counties and cost-effectiveness of a modeled nationwide screening. Cancer Causes Control 2001;12:39-45.
57. de Koning HJ. Breast cancer screening; cost-effective in practice? Eur J Radiol 2000;33:32-7.